146 related articles for article (PubMed ID: 35242214)
1. Construction of Glycolytic Regulator Gene Signature to Predict the Prognosis and Tumor Immune Cell Infiltration Levels for Prostate Cancer.
Zhang L; Wang B; Wang ZS; Guo YL; Shen H
Comput Math Methods Med; 2022; 2022():9273559. PubMed ID: 35242214
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Analysis Reveals Key Genes and Signalings Associated with the Prognosis of Prostate Cancer.
Shen H; Guo YL; Li GH; Zhao W; Zhang L
Comput Math Methods Med; 2021; 2021():9946015. PubMed ID: 34497666
[TBL] [Abstract][Full Text] [Related]
3. Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker.
Wang L; Liu X; Liu Z; Wang Y; Fan M; Yin J; Zhang Y; Ma Y; Luo J; Li R; Zhao X; Zhang P; Zhao L; Fan J; Chen Y; Lu W; Song X
Sci Rep; 2022 Jan; 12(1):192. PubMed ID: 34996995
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
Front Immunol; 2022; 13():777724. PubMed ID: 35154101
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
Front Immunol; 2021; 12():735170. PubMed ID: 34531875
[TBL] [Abstract][Full Text] [Related]
7. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
8. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
9. ARNT-dependent CCR8 reprogrammed LDH isoform expression correlates with poor clinical outcomes of prostate cancer.
Chen G; Cai ZD; Lin ZY; Wang C; Liang YX; Han ZD; He HC; Mo RJ; Lu JM; Pan B; Wu CL; Wang F; Zhong WD
Mol Carcinog; 2020 Aug; 59(8):897-907. PubMed ID: 32319143
[TBL] [Abstract][Full Text] [Related]
10. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
11. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer.
Meng J; Liu Y; Guan S; Fan S; Zhou J; Zhang M; Liang C
Cancer Med; 2019 Sep; 8(11):5202-5213. PubMed ID: 31355524
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
13. Identification of HCG18 and MCM3AP-AS1 That Associate With Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer.
Chen Y; Chen Z; Mo J; Pang M; Chen Z; Feng F; Xie P; Yang B
Technol Cancer Res Treat; 2021; 20():1533033821990064. PubMed ID: 33596783
[TBL] [Abstract][Full Text] [Related]
14. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
15. Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
Zhang Y; Mou Y; Liang C; Zhu S; Liu S; Shao P; Li J; Wang Z
Prostate; 2021 Feb; 81(3):157-169. PubMed ID: 33338276
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy.
Liang X; Wang Z; Dai Z; Zhang H; Zhang J; Luo P; Liu Z; Liu Z; Yang K; Cheng Q; Zhang M
Cancer Gene Ther; 2023 Mar; 30(3):481-496. PubMed ID: 36494582
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated miR-29c inhibits cell proliferation and glycolysis by inhibiting SLC2A3 expression in prostate cancer.
Li J; Fu F; Wan X; Huang S; Wu D; Li Y
Gene; 2018 Jul; 665():26-34. PubMed ID: 29715514
[TBL] [Abstract][Full Text] [Related]
18. Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients.
Che H; Liu Y; Zhang M; Meng J; Feng X; Zhou J; Liang C
Med Sci Monit; 2019 Dec; 25():9991-10007. PubMed ID: 31876269
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
20. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
